Label: DEXTROSE- dextrose monohydrate injection, solution

  • NDC Code(s): 0338-0017-01, 0338-0017-02, 0338-0017-03, 0338-0017-04, view more
    0338-0017-10, 0338-0017-11, 0338-0017-18, 0338-0017-31, 0338-0017-38, 0338-0017-41, 0338-0017-48, 0338-0023-02, 0338-0023-03, 0338-0023-04
  • Packager: Baxter Healthcare Corporation
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated August 12, 2020

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use DEXTROSE INJECTION safely and effectively. See full prescribing information for DEXTROSE INJECTION.
    DEXTROSE injection, for intravenous use
    Initial U.S. Approval: 1940

    RECENT MAJOR CHANGES

    Contraindications (4) 08/2019

    Warnings and Precautions (5.1, 5.2, 5.3, 5.4, 5.5, 5.6) 08/2019

    INDICATIONS AND USAGE

    Dextrose Injection is indicated as a source of water and calories. (1)

    DOSAGE AND ADMINISTRATION

    Only for intravenous infusion. (2.1)
    See full prescribing information for information on preparation, administration, dosing considerations and instructions for use. (2.1, 2.2, 2.3)

    DOSAGE FORMS AND STRENGTHS

    Injection:

    5% (0.05 grams/mL): 5 grams of dextrose hydrous per 100 mL in single-dose partial-fill flexible containers: 25 mL, 50 mL, 100 mL, 150 mL, 250 mL, 500 mL, and 1000 mL. (3)
    10% (0.1 grams/mL): 10 grams of dextrose hydrous per 100 mL in partial-fill flexible containers: 250 mL, 500 mL, and 1000 mL. (3)

    CONTRAINDICATIONS

    Clinically significant hyperglycemia. (4)
    Known hypersensitivity to dextrose. (4)

    WARNINGS AND PRECAUTIONS

    Hyperglycemia or Hyperosmolar Hyperglycemic State: Monitor blood glucose and administer insulin as needed. (5.1)
    Hypersensitivity Reactions: Monitor for signs and symptoms and discontinue infusion if reactions occur. (5.2)
    Vein Damage and Thrombosis: Consider central vein when administering more than 5% dextrose or with an osmolarity of at least 900 mOsm/L or when there is peripheral vein irritation, phlebitis, and/or associated pain. (2.2, 5.3)
    Hyponatremia: Avoid in patients with or at risk for hyponatremia. If use cannot be avoided, monitor serum sodium concentrations. (5.4)
    Electrolyte Imbalance and Fluid Overload: Avoid in patients with or at risk for fluid and/or solute overloading. If use cannot be avoided, monitor daily fluid balance, electrolyte concentrations, and acid-base balance, as needed and especially during prolonged use. (5.5)
    Refeeding Syndrome: Monitor severely undernourished patients and slowly increase nutrient intake. (5.6)

    ADVERSE REACTIONS

    The most common adverse reactions are, hyperglycemia, hypersensitivity reactions, hyponatremia, infection both systemic and at the injection site, vein thrombosis or phlebitis, and electrolyte imbalance. (6)

    To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare at 1-866-888-2472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    DRUG INTERACTIONS

    Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance: Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance. (7.1)

    USE IN SPECIFIC POPULATIONS

    Pediatric Use: Increased risk of hypoglycemia/hyperglycemia; monitor serum glucose concentrations. (8.4)

    See 17 for PATIENT COUNSELING INFORMATION.

    Revised: 8/2020

  • Table of Contents
  • 1 INDICATIONS AND USAGE

    Dextrose Injection is indicated as source of water and calories.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Important Administration Instructions

    Dextrose Injection is intended for intravenous use.
    Peripheral administration of 5% dextrose is generally acceptable, however, consider central vein when administering more than 5% dextrose or with an osmolarity of at least 900 mOsm/L or when there is peripheral vein irritation, phlebitis, and/or associated pain [see Warnings and Precautions (5.3)].
    Do not administer Dextrose Injection simultaneously with blood products through the same administration set because of the possibility of pseudoagglutination or hemolysis.
    To prevent air embolism, use a non-vented infusion set or close the vent on a vented set, avoid multiple connections, do not connect flexible containers in series, fully evacuate residual gas in the container prior to administration, do not pressurize the flexible container to increase flow rates, and if administration is controlled by a pumping device, turn off pump before the container runs dry.
    Prior to infusion, visually inspect the diluted dextrose solution for particulate matter. The solution should be clear and there should be no precipitates. Do not administer unless solution is clear and container is undamaged.
    Use of a final filter is recommended during administration of parenteral solutions, where possible.

    2.2 Recommended Dosage

    The choice of dextrose concentration, rate and volume depends on the age, weight, clinical and metabolic conditions of the patient and concomitant therapy. Electrolyte supplementation may be indicated according to the clinical needs of the patient.

    The administration rate should be governed, especially for premature infants with low birth weight, during the first few days of therapy, by the patient’s tolerance to dextrose.

    Increase the infusion rate gradually as indicated by frequent monitoring of blood glucose concentrations [ seeWarnings and Precautions (5.1), Use in Specific Populations (8.4)].

    2.3 Instructions for Use

    To Open

    Do not remove from overpouch until ready to use.
    Tear overwrap down side at slit and remove solution container. Small amounts of moisture may be found on the solution container from water permeating from inside the container. The amount of permeated water is insufficient to affect the solution significantly. If larger amounts of water are found, the container should be checked for tears or leaks.
    Visually inspect the container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Evaluate the following:
    If the outlet port protector is damaged, detached, or not present, discard container.
    Check to ensure the solution is clear and there are no precipitates. Discard if there is a color change and/or the appearance of precipitates, insoluble complexes or crystals.
    Check for minute leaks by squeezing the inner bag firmly. If leaks are found, discard container.

    Preparation for Administration

    1.
    Suspend container from eyelet support.
    2.
    Remove protector from outlet port at bottom of container.
    3.
    Attach administration set. Refer to complete directions accompanying set.

    To Add Medication

    Additives may be incompatible. Complete information is not available. Do not use additives known or determined to be incompatible.
    Consult with pharmacist, if available. If, in the informed judgment of the healthcare provider, it is deemed advisable to introduce additives, use aseptic technique.
    When introducing additives, consult the instructions for use of the medication to be added and other relevant literature.
    Before adding a substance or medication, verify that it is soluble and/or stable in Dextrose Injection and that the pH range of Dextrose Injection is appropriate.

    To Add Medication Before Solution Administration

    1.
    Prepare medication site.
    2.
    Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.
    3.
    Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.
    4.
    After addition, check to ensure the solution is clear and there are no precipitates. Discard if there is a color change and/or the appearance of precipitates, insoluble complexes or crystals.

    To Add Medication During Solution Administration

    1.
    Close clamp on the set.
    2.
    Prepare medication site.
    3.
    Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.
    4.
    Remove container from IV pole and/or turn to an upright position.
    5.
    Evacuate both ports by squeezing them while container is in the upright position.
    6.
    Mix solution and medication thoroughly.
    7.
    After addition, check to ensure the solution is clear and there are no precipitates. Discard if there is a color change and/or the appearance of precipitates, insoluble complexes or crystals, do not use.
    8.
    Return container to in-use position and continue administration.

    Storage

    Use promptly; do not store solutions containing additives.
    Single-dose container.
    Discard any unused portion.
  • 3 DOSAGE FORMS AND STRENGTHS

    Dextrose Injection, USP is a clear, sterile, non-pyrogenic solution of dextrose in single-dose containers:

    5% (0.05 grams/mL): 5 grams of dextrose hydrous per 100 mL in partial-fill flexible containers: 25 mL, 50 mL, 100 mL, 150 mL, 250 mL, 500 mL, and 1000 mL
    10% (0.1 grams/mL): 10 grams of dextrose hydrous per 100 mL in partial-fill flexible containers: 250 mL, 500 mL, and 1000 mL
  • 4 CONTRAINDICATIONS

    The use of Dextrose Injection is contraindicated in patients with:

    Clinically significant hyperglycemia [see Warnings and Precautions (5.1)].
    Known hypersensitivity to dextrose [see Warnings and Precautions (5.2)].
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Hyperglycemia and Hyperosmolar Hyperglycemic State

    The use of dextrose infusions in patients with impaired glucose tolerance may worsen hyperglycemia. Administration of dextrose at a rate exceeding the patient’s utilization rate may lead to hyperglycemia, coma, and death.

    Hyperglycemia is associated with an increase in serum osmolality, resulting in osmotic diuresis, dehydration and electrolyte losses [see Warnings and Precautions (5.5)]. Patients with underlying CNS disease and renal impairment who receive dextrose infusions, may be at greater risk of developing hyperosmolar hyperglycemic state.

    Monitor blood glucose levels and treat hyperglycemia to maintain levels within normal limits while administering Dextrose Injection. Insulin may be administered or adjusted to maintain optimal blood glucose levels during Dextrose Injection administration.

    5.2 Hypersensitivity Reactions

    Hypersensitivity and infusion reactions, including anaphylaxis, have been reported with Dextrose Injection [see Adverse Reactions (6)]. Stop infusion immediately and treat patient accordingly if signs or symptoms of a hypersensitivity reaction develop. Appropriate therapeutic countermeasures must be instituted as clinically indicated.

    5.3 Vein Damage and Thrombosis

    Peripheral administration of 5% Dextrose Injection is generally acceptable, however, consider central vein when administering more than 5% dextrose or with an osmolarity of ≥ at least 900 mOsm/L or when there is peripheral vein irritation, phlebitis, and/or associated pain [see Dosage and Administration (2. 1)]. The infusion of hypertonic solutions into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis. The primary complication of peripheral access is venous thrombophlebitis, which manifests as pain, erythema, tenderness or a palpable cord. Remove the catheter as soon as possible, if thrombophlebitis develops.

    5.4 Hyponatremia

    10% Dextrose Injection is a hypertonic solution [see Description, Table 1 (11)]. In the body, however, glucose containing fluids can become extremely physiologically hypotonic due to rapid glucose metabolization. Monitoring of serum sodium is particularly important for hypotonic fluids.

    Depending on the tonicity of the solution, the volume and rate of infusion, and depending on a patient’s underlying clinical condition and capability to metabolize glucose, intravenous administration of glucose can cause electrolyte disturbances, most importantly hypo- or hyperosmotic hyponatremia. Monitor serum sodium to minimize the risk of hyponatremia.

    The risk for hyponatremia is increased in pediatric patients, elderly patients, postoperative patients, those with psychogenic polydipsia, and in patients treated with medications that increase the risk of hyponatremia (such as diuretics, certain antiepileptic and psychotropic medications). Close clinical monitoring may be warranted.

    Acute hyponatremia can lead to acute hyponatremic encephalopathy characterized by headache, nausea, seizures, lethargy and vomiting. Patients with brain edema are at particular risk of severe, irreversible and life-threatening brain injury. Patients at increased risk for developing complications of hyponatremia, such as hyponatremic encephalopathy include pediatric patients; women, in particular, premenopausal women; patients with hypoxemia; and in patients with underlying central nervous system disease [see Use in Specific Populations (8.4, 8.5)].

    Avoid Dextrose Injection in patients with or at risk for hyponatremia. If use cannot be avoided, monitor serum sodium concentrations.

    Rapid correction of hyponatremia is potentially dangerous with risk of serious neurologic complications. Brain adaptations reducing risk of cerebral edema make the brain vulnerable to injury when chronic hyponatremia is too rapidly corrected, which is known as osmotic demyelination syndrome (ODS). To avoid complications, monitor serum sodium and chloride concentrations, fluid status, acid-base balance, and signs of neurologic complications.

    High volume infusion must be used with close monitoring in patients with cardiac or pulmonary failure, and in patients with non-osmotic vasopressin release (including SIADH), due to the risk of hospital-acquired hyponatremia.

    5.5 Electrolyte Imbalance and Fluid Overload

    Electrolyte deficits, particularly in serum potassium and phosphate, may occur during prolonged use of concentrated dextrose solutions.

    Depending on the volume and rate of infusion, the patient’s underlying clinical condition and capability to metabolize dextrose, intravenous administration of Dextrose Injection can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, (including hypoosmotic hyponatremia), overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations in the administered solution. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations in the solution.

    Avoid Dextrose Injection in patients with or at risk for fluid and/or solute overloading. If use cannot be avoided, monitor fluid balance, blood electrolyte levels, concentration of glucose, acid-base balance, correct fluid and electrolyte imbalances during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation and acid-base balance as needed and especially during prolonged use. Additional monitoring is recommended for patients with water and electrolyte disturbances that could be aggravated by increased glucose, insulin administration and/or free water load. Patients at increased risk for developing hyponatremic encephalopathy include pediatric patients; elderly patients, women, in particular premenopausal women; patients with hypoxemia; and patients with underlying CNS disease [see Use in Specific Populations (8.4, 8.5)].

    5.6 Refeeding Syndrome

    Refeeding severely undernourished patients may result in refeeding syndrome, characterized by the intracellular shift of potassium, phosphorus, and magnesium as the patient becomes anabolic. Thiamine deficiency and fluid retention may also develop. To prevent these complications, monitor severely undernourished patients and slowly increase nutrient intake.

  • 6 ADVERSE REACTIONS

    The following adverse reactions associated with the use of dextrose injection were identified in clinical trials or postmarketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency, reliably, or to establish a causal relationship to drug exposure.

    The following clinically significant adverse reactions are described elsewhere in the labeling:

    Hyperglycemia and hyperosmolar hyperglycemic state [see Warnings and Precautions (5.1)]
    Hypersensitivity Reactions: anaphylaxis, pruritis, bronchospasm, cyanosis, angioedema, hypotension, pyrexia, chills, and rash [see Warnings and Precautions (5.2)]
    Infusion Site Reactions: infusion site phlebitis, infusion site erythema, vein damage and thrombosis, and infusion site thrombophlebitis (10% dextrose only) [see Warnings and Precautions (5.3)]
    Hyponatremia and hyponatremic encephalopathy [see Warnings and Precautions (5.4)]
    Electrolyte imbalance, fluid overload andhypervolemia [see Warnings and Precautions (5.5)]
    Refeeding syndrome [see Warnings and Precautions (5.6)]
    Pulmonary vascular precipitates (10% dextrose only)
  • 7 DRUG INTERACTIONS

    7.1 Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance

    Dextrose Injection can affect glycemic control, vasopressin and fluid and/or electrolyte balance [see Warnings and Precautions (5.1, 5.4, 5.5)]. Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance when using Dextrose Injection in patients treated with other substances that affect glycemic control, vasopressin or fluid and/or electrolyte balance.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Appropriate administration of Dextrose Injection during pregnancy is not expected to cause adverse developmental outcomes, including congenital malformations. Animal reproduction studies have not been conducted with injectable dextrose solutions.

    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

    8.2 Lactation

    Risk Summary

    There are no data on the presence of dextrose in human milk, the effects on a breastfed infant, or the effects on milk production. The lack of clinical data during lactation precludes a clear determination of the risk of Dextrose Injection to an infant during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Dextrose Injection and any potential adverse effects on the breastfed infant from Dextrose Injection or from the underlying maternal condition.

    8.4 Pediatric Use

    The safety profile of Dextrose Injection in pediatric patients is similar to adults.

    Neonates, especially premature infants with low birth weight, are at increased risk of developing hypo- or hyperglycemia and therefore need close monitoring during treatment with intravenous glucose infusions to ensure adequate glycemic control in order to avoid potential long-term adverse effects.

    Closely monitor plasma electrolyte concentrations in pediatric patients who may have impaired ability to regulate fluids and electrolytes. In very low birth weight infants, excessive or rapid administration of Dextrose Injection may result in increased serum osmolality and risk of intracerebral hemorrhage.

    Children (including neonates and older children) are at increased risk of developing hyponatremia as well as for developing hyponatremic encephalopathy [see Warnings and Precautions (5.4)].

    8.5 Geriatric Use

    Clinical studies of Dextrose Injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Elderly patients are at increased risk of developing hyponatremia as well as for developing hyponatremic encephalopathy [see Warnings and Precautions (5.4)]. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

    Dextrose is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

  • 10 OVERDOSAGE

    An increased infusion rate of Dextrose Injection or administration of dextrose solutions can cause hyperglycemia, hyperosmolality, and adverse effects on water and electrolyte balance [see Warnings and Precautions (5.1, 5.5)].

    Severe hyperglycemia and severe dilutional hyponatremia, and their complications, can be fatal. Discontinue infusion, reduce dose and institute appropriate corrective measures such as administration of exogenous insulin.

    Discontinue infusion and institute appropriate corrective measures in the event of overhydration or solute overload during therapy, with particular attention to CNS, respiratory and cardiovascular systems.

    If over-exposure occurs, call your Poison Control Center at 1-800-222-1222 for current information on the management of poisoning or overdosage.

  • 11 DESCRIPTION

    Dextrose Injection, 5% and 10% USP are sterile, non-pyrogenic solutions of Dextrose, USP in Water for Injection in a polyvinylchloride flexible plastic container for intravenous administration as a source of water and calories.

    Partial-fill containers, designed to facilitate admixture when necessary, are available in 25 mL, 50 mL, 100 mL, 150 mL, 250 mL, 500 mL, and 1000 mL sizes. See Table 1 for the content and characteristics of this solution.

    The solution contains no bacteriostatic, antimicrobial agent or added buffer and is intended only for use as a single-dose injection. The pH range is 4.0 (3.2 to 6.5).

    Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly.

    Table 1. Contents and Characteristics of Dextrose Injection 5% and 10%, USP
    StrengthFill VolumeAmount of Dextrose Hydrous per Containerkcal*per ContainerOsmolarity (mOsmol per liter)
    *
    Caloric value calculated on the basis of 3.4 kcal/g of dextrose, hydrous

    Dextrose Injection 5%, USP
    (0.05 grams/mL)

    25 mL
    Quad pack

    1.25 grams

    4.25

    252

    50 mL
    Single pack
    Quad pack
    Multi pack

    2.5 grams

    8.5

    252

    100 mL
    Single pack
    Quad pack
    Multi pack

    5 grams

    17

    252

    150 mL

    7.5 grams

    25.5

    252

    250 mL

    12.5 grams

    42.5

    252

    500 mL

    25 grams

    85

    252

    1000 mL

    50 grams

    170

    252

    Dextrose Injection 10%, USP
    (0.1 grams/mL)

    250 mL

    25 grams

    85

    505

    500 mL

    50 grams

    170

    505

    1000 mL

    100 grams

    340

    505

    Dextrose, USP is chemically designated D-glucose, monohydrate (C6H12O6 • H2O), a hexose sugar freely soluble in water. The molecular weight of dextrose (D-glucose) monohydrate is 198.17. It has the following structural formula:

    Dextrose Hydrous Structural Formula

    Water for Injection, USP is chemicaly designated H2O.

    Dextrose is derived from corn.

    The VIAFLEX Plus plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). VIAFLEX Plus on the container indicates the presence of a drug additive in a drug vehicle. The VIAFLEX Plus plastic container system utilizes the same container as the VIAFLEX plastic container system. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Dextrose is oxidized to carbon dioxide and water, yielding energy.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Dextrose Injection 5% and 10%, USP are clear, colorless, sterile solutions of dextrose supplied in a single-dose, partial-fill flexible containers.

    Product Description

    Size

    Code

    NDC

    Dextrose Injection 5%, USP
    (0.05 grams/mL)

    25 mL
    Quad pack

    2B0080

    0338-0017-10

    50 mL
    Single pack
    Quad pack
    Multi pack


    2B0086
    2B0081
    2B0088


    0338-0017-41
    0338-0017-11
    0338-0017-31

    100 mL
    Single pack
    Quad pack
    Multi pack


    2B0087
    2B0082
    2B0089


    0338-0017-48
    0338-0017-18
    0338-0017-38

    150 mL
    250 mL
    500 mL
    1000 mL

    2B0061
    2B0062
    2B0063
    2B0064

    0338-0017-01
    0338-0017-02
    0338-0017-03
    0338-0017-04

    Dextrose Injection 10%, USP
    (0.1 grams/mL)

    250 mL
    500 mL
    1000 mL

    2B0162
    2B0163
    2B0164

    0338-0023-02
    0338-0023-03
    0338-0023-04

    Do not remove container from the overwrap until intended for use.

    Use the product immediately after mixing and the introduction of additives.

    Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C/77°F); brief exposure up to 40°C/104°F does not adversely affect the product.

  • 17 PATIENT COUNSELING INFORMATION

    Inform patients, caregivers, or home healthcare providers of the following risks of Dextrose Injection:

    Hyperglycemia and hyperosmolar hyperglycemic state [see Warnings and Precautions (5.1)]
    Hypersensitivity reactions [see Warnings and Precautions (5.2)]
    Vein damage and thrombosis [see Warnings and Precautions (5.3)]
    Hyponatremia [see Warnings and Precautions (5.4)]
    Electrolyte imbalance and fluid overload [see Warnings and Precautions (5.5)]
    Refeeding syndrome [see Warnings and Precautions (5.6)]

    Manufactured by, Packed by, Distributed by:

    Baxter Healthcare Corporation
    Deerfield, IL 60015 USA
    Printed in USA

    07-19-00-1441

    Baxter and Viaflex are trademarks of Baxter International Inc.

  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL

    Dextrose Representative Container Label

    Container Label

    Container Label

    LOT

    EXP

    5% Dextrose
    Injection USP

    2B0061
    NDC 0038-0017-01

    150 mL

    Each 100 mL contains
    5 g DextroseHydrous
    USP pH 4.0 (3.2 to 6.5)
    Osmolarity 252 mOsmol/L (calc)
    SterileNonpyrogenic Single dose
    container Read package insert for full
    information Additives may be
    incompatible Dosage Intravenously as
    directed by a physician Cautions
    Squeeze and inspect inner bag which
    maintains product sterility Discard if
    leaks are found Must not be used in
    series connections Do not administer
    simultaneously with blood Do not
    useunless solution is clear Rx Only
    Store unit in moisture barrier overwrap
    at room temperature(25°C/77°F) until
    ready to use Avoid excessive heat See
    insert

    Viaflex container PL146 plastic

    BAXTER VIAFLEX and PL 146 are
    trademarks of Baxter International Inc

    For product information 1-800-933-0303

    Baxter
    Baxter Healthcare Corporation
    Deerfield, IL 60015 USA
    Made in USA

    Dextrose Representative Carton Label

    Carton Label

    Carton Label

    2B0061

    36-150 ML

    VIAFLEX(R) CONTAINER

    5% DEXTROSE INJECTION, USP

    SECONDARY BAR CODE
    (17) YYMMOO (10) XXXXX

    PRIMARY BAR CODE
    (01) 5030338017015

    EXP
    XXXXX

    LOT
    XXXXX

    Representative Container Label NDC 0338-0023-03

    Container Label

    Container Label

    LOT

    EXP

    2B0063
    NDC 0038-0023-03
    DIN 00060364

    10% Dextrose
    Injection USP

    500 mL

    Each 100 mL contain 10 g Dextrose Hydrous USP
    pH 4.0 (3.2 to 6.5) Hypertonic Osmolarity 505
    mOsmol/L (calc) Sterile Nonpyrogenic Single dose
    container Additives may be incompatible Consult with
    pharmacist if available When introducing additives use
    aseptic technique Mix thorouhly Do not store
    Dosage Intravenously as directed by a physician See
    cirections Cautions Squeeze and inspect inner bag
    which maintains product sterility Discard if leaks are
    found Must not be used in series connections Do not
    administer simultaneously with blood Do not use
    unless solution is clear Rx Only Store unit in
    moisture barrier overwrap at room temperature
    (25°C/77°F) until ready to use Avoid excessive heat
    See insert

    Viaflex container PL 146 plastic

    BAXTER VIAFLEX and PL 146 are trademarks of
    Baxter International Inc

    For product information 1-800-933-0303

    Baxter logo
    Baxter Healthcare Corporation
    Deerfield, IL 60015 USA
    Made in USA

    Distribute in Canada By
    Baxter Corporation
    Toronto Ontario Canada

    Representative Carton Label 0338-0023-03

    Carton Label

    Carton Label

    2B0063Q

    24-500 ML

    VIAFLEX(R) CONTAINER

    10% DEXTROSE INJECTION, USP

    SECONDARY BAR CODE
    (17) YYMMOO (10) XXXXX

    PRIMARY BAR CODE
    (01) 50303380023030

    EXP
    XXXXX

    LOT
    XXXXX

  • INGREDIENTS AND APPEARANCE
    DEXTROSE 
    dextrose monohydrate injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0338-0017
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK) DEXTROSE MONOHYDRATE50 g  in 1000 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0338-0017-104 in 1 POUCH03/04/1971
    125 mL in 1 BAG; Type 0: Not a Combination Product
    2NDC:0338-0017-411 in 1 PACKAGE03/04/1971
    250 mL in 1 BAG; Type 0: Not a Combination Product
    3NDC:0338-0017-114 in 1 POUCH03/04/1971
    350 mL in 1 BAG; Type 0: Not a Combination Product
    4NDC:0338-0017-3116 in 1 POUCH03/04/1971
    450 mL in 1 BAG; Type 0: Not a Combination Product
    5NDC:0338-0017-481 in 1 PACKAGE03/04/1971
    5100 mL in 1 BAG; Type 0: Not a Combination Product
    6NDC:0338-0017-184 in 1 POUCH03/04/1971
    6100 mL in 1 BAG; Type 0: Not a Combination Product
    7NDC:0338-0017-3816 in 1 POUCH03/04/1971
    7100 mL in 1 BAG; Type 0: Not a Combination Product
    8NDC:0338-0017-01150 mL in 1 BAG; Type 0: Not a Combination Product03/04/1971
    9NDC:0338-0017-02250 mL in 1 BAG; Type 0: Not a Combination Product03/04/1971
    10NDC:0338-0017-03500 mL in 1 BAG; Type 0: Not a Combination Product03/04/1971
    11NDC:0338-0017-041000 mL in 1 BAG; Type 0: Not a Combination Product03/04/1971
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01667303/04/1971
    DEXTROSE 
    dextrose monohydrate injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0338-0023
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    DEXTROSE MONOHYDRATE (UNII: LX22YL083G) (ANHYDROUS DEXTROSE - UNII:5SL0G7R0OK) DEXTROSE MONOHYDRATE100 g  in 1000 mL
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0338-0023-02250 mL in 1 BAG; Type 0: Not a Combination Product01/25/1971
    2NDC:0338-0023-03500 mL in 1 BAG; Type 0: Not a Combination Product01/25/1971
    3NDC:0338-0023-041000 mL in 1 BAG; Type 0: Not a Combination Product01/25/1971
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA01669401/25/1971
    Labeler - Baxter Healthcare Corporation (005083209)
    Establishment
    NameAddressID/FEIBusiness Operations
    Baxter Healthcare Corporation059140764ANALYSIS(0338-0017, 0338-0023) , MANUFACTURE(0338-0017, 0338-0023) , LABEL(0338-0017, 0338-0023) , PACK(0338-0017, 0338-0023) , STERILIZE(0338-0017, 0338-0023)
    Establishment
    NameAddressID/FEIBusiness Operations
    Baxter Healthcare Corporation194684502ANALYSIS(0338-0017, 0338-0023)
    Establishment
    NameAddressID/FEIBusiness Operations
    Baxter Healthcare Corporation091171389ANALYSIS(0338-0017) , MANUFACTURE(0338-0017) , LABEL(0338-0017) , PACK(0338-0017) , STERILIZE(0338-0017)
    Establishment
    NameAddressID/FEIBusiness Operations
    Baxter Healthcare Corporation189326168ANALYSIS(0338-0017, 0338-0023) , MANUFACTURE(0338-0017, 0338-0023) , LABEL(0338-0017, 0338-0023) , PACK(0338-0017, 0338-0023) , STERILIZE(0338-0017, 0338-0023)
    Establishment
    NameAddressID/FEIBusiness Operations
    Baxter, S.A. de C.V.810432484ANALYSIS(0338-0017) , MANUFACTURE(0338-0017) , LABEL(0338-0017) , PACK(0338-0017) , STERILIZE(0338-0017)
    Establishment
    NameAddressID/FEIBusiness Operations
    Bieffe Medital SA464755693ANALYSIS(0338-0017) , LABEL(0338-0017) , MANUFACTURE(0338-0017) , PACK(0338-0017) , STERILIZE(0338-0017)